NCT00536744

Brief Summary

The purpose of this study is to compare the safety and effectiveness of the dermaPACE Device to sham application, when administered in conjunction with standard treatments used in the treatment of DFUs.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
206

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Oct 2007

Typical duration for phase_3

Geographic Reach
3 countries

23 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 28, 2007

Completed
3 days until next milestone

Study Start

First participant enrolled

October 1, 2007

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2010

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2010

Completed
3.6 years until next milestone

Results Posted

Study results publicly available

April 14, 2014

Completed
Last Updated

April 14, 2014

Status Verified

March 1, 2014

Enrollment Period

2.7 years

First QC Date

September 26, 2007

Results QC Date

March 7, 2014

Last Update Submit

March 7, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.

    12 weeks post initial application

Secondary Outcomes (1)

  • Time to Wound Closure, Wound Closure Area and Volume Between Active and Control 12 Weeks Post Initial Application, Subject Pain Assessment Between Active and Control 24 Weeks Post Initial Application

    12 weeks post initial application and 24 weeks post initial application

Study Arms (2)

Active PACE application - 4 applications

ACTIVE COMPARATOR

Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care

Device: acoustical pulse energy (extracorporeal shockwave)

Inactive, non-energy application

SHAM COMPARATOR

Non-energized (inactive - Sham)) application + standard of care

Other: Sham

Interventions

Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.

Also known as: dermaPACE
Active PACE application - 4 applications
ShamOTHER

Non-energized (inactive - Sham) application + standard of care

Inactive, non-energy application

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female ≥ 18 years of age
  • Diabetes mellitus
  • One or more chronic foot ulcers (only one will be treated) that are located in the ankle area or below that has persisted a minimum of 30 days prior to the Screening visit
  • HbA1c ≤ 12%
  • Diabetic Foot Ulcers ≥ 1 cm2 and ≤ 16 cm2
  • Ulcer Grade I or II, Stage A according to the University of Texas Diabetic Wound Classification system
  • Ankle Brachial Index (ABI) ≥ 0.7 and ≤ 1.2, OR toe pressure \> 50 mmHg, OR tcPO2\> 40 mmHg.

You may not qualify if:

  • Subject is morbidly obese (Body Mass Index ≥ 40)
  • Subjects on dialysis
  • Diagnosis of foot ulcer involving osteomyelitis
  • Has evidence of prior ulcer in the same area
  • Multiple diabetic foot ulcers on the foot that either are connected by fistulas or are within 5 cm of the target ulcer
  • Subject's foot ulcer intended for study application has decreased in volume by 50% or more at the end of the two-week Run-in period as compared to the Screening visit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (23)

Phoenix VA Health Care System

Phoenix, Arizona, 85012, United States

Location

HOPE Research Insititute

Phoenix, Arizona, 85050, United States

Location

Southern Arizona VA Healthcare System (SAVAHCS)

Tucson, Arizona, 85723, United States

Location

Center for Clinical Research

Castro Valley, California, 94115, United States

Location

Veterans Administration Long Beach Healthcare

Long Beach, California, 90822, United States

Location

Olive View - UCLA Medical Center

Sylmar, California, 91342, United States

Location

North American Center for Limb Preservation

New Haven, Connecticut, 06515, United States

Location

Fairfield County Foot Surgeons

Norwalk, Connecticut, 06851, United States

Location

Emory Orthopedic and Spine Center

Atlanta, Georgia, 30329, United States

Location

Northwestern Univ. Div. of Plastic Surgery

Chicago, Illinois, 60611, United States

Location

Boston Medical Center

Boston, Massachusetts, 02118, United States

Location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

Center for Palliative Wound Care; Calvary Hospital

The Bronx, New York, 10461, United States

Location

St. Vincent's Charity Hospital

Cleveland, Ohio, 44115, United States

Location

Ohio State University

Columbus, Ohio, 43221, United States

Location

Nashville Family Footcare

Nashville, Tennessee, 37203, United States

Location

Richard Galperin, DPM, PA

Dallas, Texas, 75224, United States

Location

Complete Family Foot Care

McAllen, Texas, 78501, United States

Location

Robert Wunderlich, DPM, PA

San Antonio, Texas, 78212, United States

Location

Aurora Health Care

Milwaukee, Wisconsin, 53215, United States

Location

Mathias Spital

Rheine, 48431, Germany

Location

Kings College Hospital

London, SE59RS, United Kingdom

Location

Related Links

MeSH Terms

Conditions

Diabetic Foot

Interventions

salicylhydroxamic acid

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Results Point of Contact

Title
Dr. Daniel Jorgensen, MD
Organization
SANUWAVE, Inc.

Study Officials

  • Daniel Jorgensen, MD

    SANUWAVE, Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 26, 2007

First Posted

September 28, 2007

Study Start

October 1, 2007

Primary Completion

June 1, 2010

Study Completion

September 1, 2010

Last Updated

April 14, 2014

Results First Posted

April 14, 2014

Record last verified: 2014-03

Locations